Current anti-inflammatory therapeutics for atherosclerosis studied in randomized clinical trials specifically target IL-1β (canakinumab in the CANTOS trial [66]), IL-6 (ziltivekimab in RESCUE, ZEUS [188], and clazakizumab in the POSIBIL6ESKD trials [189]) or have a broader anti-inflammatory function, as with colchicine (as shown in the COLCOT [190], LoDoCo2 [191], COPS [192], CLEAR-SYNERGY [193], and CONVINCE [194] trials) and methotrexate (the CIRT trial [195]). This evidence concerns the gene IL1B and atherosclerosis.